Genetic Cardiomyopathies Market Outlook (2023 to 2033)
As per Future Market Insights, the genetic cardiomyopathies market is anticipated to attain a value pool of US$ 2 billion by 2023-end. Global disbursement of genetic cardiomyopathies is expected to rise at a CAGR of 13.3% to US$ 7 billion in 2033.
| Data Points |
Key Statistics |
| Expected Market Value in 2023 |
US$ 2 billion |
| Projected Market Value in 2033 |
US$ 7 billion |
| Growth Rate (2023 to 2033) |
13.3% CAGR |
Awareness and Screening Programs: Identifying At-Risk Individuals for Early Intervention
- Increasing prevalence of genetic cardiomyopathies: Genetic cardiomyopathies are a group of inherited cardiovascular disorders that affect the structure and function of the heart muscle. The prevalence of these disorders is increasing worldwide, which is driving the growth of the genetic cardiomyopathies market. According to a study published in the Journal of the American College of Cardiology, genetic cardiomyopathies account for up to 30% of all cases of dilated cardiomyopathy.
- Advances in genetic testing technologies: Genetic testing is an important tool for the diagnosis and management of genetic cardiomyopathies. Advances in genetic testing technologies have made it easier and more cost-effective to identify genetic mutations associated with these disorders. The development of next-generation sequencing (NGS) technologies has enabled the simultaneous analysis of multiple genes, allowing for more comprehensive genetic testing.
- Increasing awareness and screening programs: Increased awareness of genetic cardiomyopathies among physicians and patients has led to the implementation of screening programs for at-risk individuals. These screening programs help identify individuals who may be carriers of genetic mutations and allow for early intervention and management. The implementation of these programs is driving the growth of the genetic cardiomyopathies market.
- Growing demand for personalized medicine: Genetic testing and molecular diagnostics have paved the way for personalized medicine, which tailors treatment to the individual genetic makeup of the patient. The development of targeted therapies for specific genetic mutations associated with genetic cardiomyopathies is driving the growth of the market.
Artificial Intelligence and Machine Learning Improve Diagnosis and Clinical Trials
- Development of novel therapies: There is a significant unmet need for effective therapies for genetic cardiomyopathies. The development of novel therapies that target specific genetic mutations associated with these disorders is a prominent opportunity for the genetic cardiomyopathies market.
- Expansion of genetic testing services: The expansion of genetic testing services to underserved populations and the development of low-cost testing options can increase the adoption of genetic testing for the diagnosis and management of genetic cardiomyopathies.
- Integration of artificial intelligence and machine learning: The integration of artificial intelligence and machine learning technologies in genetic testing and diagnosis can improve the accuracy and speed of diagnosis and increase the efficiency of clinical trials.
- Development of non-invasive diagnostic tools: Non-invasive diagnostic tools such as imaging and biomarkers can provide a less invasive alternative to traditional diagnostic methods, increasing patient comfort and compliance. The development of non-invasive diagnostic tools is a significant opportunity for the genetic cardiomyopathies market.
Gene Editing and Gene Therapy: Revolutionary Treatments for Genetic Cardiomyopathies
- Adoption of gene editing and gene therapy: Advances in gene editing and gene therapy technologies are providing new treatment options for genetic cardiomyopathies. These technologies have the potential to correct genetic mutations associated with these disorders, providing a cure rather than just symptom management.
- Emergence of direct-to-consumer genetic testing: Direct-to-consumer genetic testing services are becoming increasingly popular, allowing individuals to access genetic testing without the need for a healthcare provider. This trend is likely to increase the adoption of genetic testing for genetic cardiomyopathies.
- Shift towards value-based healthcare: There is a growing trend towards value-based healthcare, which focuses on improving patient outcomes while reducing costs. This trend is driving the development of more effective and efficient diagnostic and treatment options for genetic cardiomyopathies.
Genetic cardiomyopathies are inherited type of medical condition of the heart muscles, some of the most common inherited disorders and are a major cause of heart disease in all age groups. It is characterized by the weakening of heart muscles that makes it harder for the heart to pump blood to the rest of the body. The main types of genetic cardiomyopathies are dilated, restrictive and hypertonic cardiomyopathy.
The treatment of genetic cardiomyopathies include medications, surgically implanted devices or a heart transplant. The market of genetic cardiomyopathies is expected to grow rapidly during the forecast period due to the rising number of heart problems and increasing life expectancy of individuals. The outbreak of coronavirus is an unprecedented shock to the world’s economy.
As coronavirus has become the main focus, all research institutes, biotech and pharmaceutical companies are appointed in collaboration work to deal with Covid-19. There has been a disruption in the supply chain due to which production of implants and development of drugs is adversely affected.
Genetic Cardiomyopathies Market: Drivers and Restraints
There are many factors that are driving the genetic cardiomyopathies market, advancement in understanding and managing of genetic cardiomyopathies is the major factor. The increasing demand for early diagnosis and treatment of congestive heart failure, heart attack, and coronary heart disease is likely to drive the growth of the genetic cardiomyopathies market.
Also, the increasing use of minimally invasive technology and availability of remote monitoring solutions, medical tourism in emerging countries are expected to boost the market. Apart from drivers, there are few restraints of genetic cardiomyopathies market such as high diagnosis and treatment cost and lack of public awareness about various heart disorders.
Genetic Cardiomyopathies Market: Overview
Based on the type of disease, the dilated cardiomyopathy is expected to hold a major share in the genetic cardiomyopathies market. Based on the drug type, the anticoagulant is the most preferred segment of the genetic cardiomyopathies market, anti-hypertensive drug is expected to grow during the forecast period. Based on the end-user, the hospitals are expected to have the largest share in the global genetic cardiomyopathies market.
Genetic Cardiomyopathies Market: Region-wise Outlook
North America and Europe are expected to dominate the global genetic cardiomyopathies market, due to the increasing prevalence of the cardiac disorder, technological advancements, and the presence of key market players in the region. Asia-Pacific is expected to have a significant growth in the global genetic cardiomyopathies market over the forecast period due to the rising focus on precision medicine, and rising awareness of cardiac disorders.
The increasing population and changing lifestyle in countries like China and India is further likely to increase the demand for genetic cardiomyopathies in the region. The advancement in the technologies and the development of direct sarcomere modulators is successful in providing a better and detailed understanding of the molecular mechanisms.
Also, there has been a substantial progress in drug therapy for the management of genetic cardiomyopathies such as beta-andregenic blockers. There are many ongoing clinical trials of several drugs that would help to manage heart disorders in a better way.
Genetic Cardiomyopathies Market: Key Market Participants
Some of the market participants in the global genetic cardiomyopathies market identified across the value chain include:
- Novartis International AG
- Merck & Co.
- Teva Pharmaceuticals Industries Ltd.
- Mylan N.V
- Bristol Myers Squibb Company
- Boston Scientific Corporation
- Becton
- Dickinson and Company
- Critical Care Diagnostics Inc.
- LabCorp
- PerkinElmer
- Sofina
- Bio-Rad Laboratories Inc.
- Roche Holding AG
- AstraZeneca PLC
- Sanofi S.A
- MyoKardia
- PhaseBio
The report covers exhaust analysis on
- Genetic Cardiomyopathies Market Segments
- Genetic Cardiomyopathies Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (USA, Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, United Kingdom, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, ASEAN, Australia & New Zealand)
- China
- Japan
- Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
